Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Australia "strongly commends" revised guidelines for cervical smear tests:

This article was originally published in Clinica

Executive Summary

Australia's National Health and Medical Research Council (NHMRC) has expressed its support for the national cervical screening programme, which it recently revised to keep it consistent with international best practice. The council has recommended that the screening interval in Australia also be reviewed at the earliest opportunity. Screening to prevent cancer: guidelines for the management of asymptomatic women with screen-detected abnormalities, was developed to help achieve the best outcomes in the management of abnormal Pap test results; it will also raise women's awareness of the usefulness of Pap smears in preventing death from cervical cancer. Professor Ian Hammond, chairman of the guidelines review group, strongly commended the guidelines.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT055814

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel